Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
about
Repurposing psychiatric medicines to target activated microglia in anxious mild cognitive impairment and early Parkinson's diseaseDocosahexaenoic Acid and Cognition throughout the LifespanDrug development in Alzheimer's disease: the path to 2025Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's diseaseApproaches for discovering anti-prion compounds: lessons learned and challenges ahead.Alzheimer's disease drug development pipeline: 2017.A Librarian’s Role in Improving Rigor in Research—AlzPED: Alzheimer’s Disease Preclinical Efficacy Database
P2860
Q26748711-104A4AC0-52FD-41DE-9D11-DE7A16346E88Q26768442-7DD25BF4-F892-4C39-8777-B6504B7D4190Q27007748-F6938751-2E60-48CE-A8E2-95E82862C142Q27024122-2EAF798D-EE66-47CE-B7F3-7C430D7ED0DEQ38356026-D3BFD184-BB04-41D8-AB27-2D285D4C210DQ42655757-9711469A-F22E-4A18-B25B-A27E21EB2A55Q58518784-5F63115D-84AA-4AD4-B89E-8019290A1628
P2860
Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
@en
Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
@nl
type
label
Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
@en
Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
@nl
prefLabel
Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
@en
Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
@nl
P2860
P1476
Repackaging FDA-approved drugs for degenerative diseases: promises and challenges.
@en
P2093
Jeffrey L Cummings
Kate Zhong
P2860
P304
P356
10.1586/17512433.2014.884923
P407
P577
2014-02-06T00:00:00Z